Affordable Access

deepdyve-link
Publisher Website

Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.

Authors
  • Häggström, J
  • Boswood, A
  • O'Grady, M
  • Jöns, O
  • Smith, S
  • Swift, S
  • Borgarelli, M
  • Gavaghan, B
  • Kresken, J-G
  • Patteson, M
  • Åblad, B
  • Bussadori, C M
  • Glaus, T
  • Kovačević, A
  • Rapp, M
  • Santilli, R A
  • Tidholm, A
  • Eriksson, A
  • Belanger, M C
  • Deinert, M
  • And 13 more
Type
Published Article
Journal
Journal of veterinary internal medicine / American College of Veterinary Internal Medicine
Publication Date
Jan 01, 2013
Volume
27
Issue
6
Pages
1441–1451
Identifiers
DOI: 10.1111/jvim.12181
PMID: 24010489
Source
Medline
Keywords
License
Unknown

Abstract

Pimobendan versus benazepril resulted in similar QoL during the study, but conferred increased time before intensification of CHF treatment. Pimobendan treatment resulted in smaller heart size, higher body temperature, and less retention of free water.

Report this publication

Statistics

Seen <100 times